




CME FOUNDATION OF INDIA



**NOVEL THERAPY TO
TREAT CKD ANEMIA IN INDIA**

EVENT REPORT

About Workshop

The **CME Foundation of India**, organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 14th January 2026 at ESIC Hospital, Faridabad. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by **Dr. Jitendra Kumar**, covered various aspects of CKD anemia management such as understanding the escalating challenge in CKD anemia, gaps in existing therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

Date: 14th January 2026
Venue: ESIC Hospital, Faridabad
No. of participants: 30

Agenda

Date: 14th January 2026

Time: 1:00 p.m. to 2:00 p.m.

Topics	Speaker	Timings
Registration		1:00 p.m. – 1:10 p.m.
Welcome Note		1:10 p.m. – 1:15 p.m.
Novel Therapy to Treat CKD Anemia in India	Dr. Jitendra Kumar M.B.B.S., M.D. (Medicine), D.N.B. (Medicine), D.M. (Nephrology), FISN	1:15 p.m. – 1:55 p.m.
Vote of Thanks		1:55 p.m. – 2:00 p.m.

Summary of the Novel Therapy to Treat CKD Anemia in India

CKD-Related Anemia in India: An Escalating Clinical and Public Health Concern

Dr. Jitendra Kumar initiated the session by underscoring the escalating burden of chronic kidney disease (CKD)-related anemia in India, highlighting its far-reaching consequences on patient morbidity, overall quality of life, and healthcare expenditure. He emphasized that anemia in CKD is a complex and multifactorial condition resulting from a convergence of factors such as iron deficiency, chronic inflammation, and diminished endogenous erythropoietin production. Dr. Jitendra Kumar noted that the interplay of these underlying mechanisms significantly complicates diagnosis and management, reinforcing the urgent need for innovative and comprehensive treatment strategies that extend beyond conventional therapeutic approaches.

Limitations in Existing Therapies

The discussion subsequently focused on currently available treatment modalities, including erythropoiesis-stimulating agents (ESAs) and iron supplementation. Dr. Jitendra Kumar highlighted several inherent limitations associated with these therapies, including inconsistent clinical efficacy, potential safety concerns, and restricted accessibility within the Indian healthcare landscape. He pointed out that these challenges frequently result in inadequate hemoglobin control, frequent treatment modifications, and suboptimal patient adherence. Collectively, these factors contribute to persistent clinical and operational gaps in the effective management of CKD-related anemia.

Desidustat: Advancing the Treatment Paradigm for CKD-Related Anemia

A key highlight of the workshop was the introduction and discussion of Desidustat, a novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Jitendra Kumar explained that Desidustat functions by stimulating the body's physiological erythropoietin production, enhancing iron mobilization and utilization, and reducing elevated hepcidin levels. By addressing multiple pathophysiological pathways involved in CKD-related anemia, Desidustat represents a potentially safer, more holistic, and convenient oral alternative to traditional ESA therapy. Its oral administration reduces dependence on frequent injections and may lead to improved treatment adherence and patient convenience.

Real World Evidence Supporting Desidustat Use

Dr. Jitendra Kumar presented data from pivotal clinical trials demonstrating Desidustat's efficacy in achieving and sustaining stable hemoglobin levels across a broad spectrum of CKD patient populations. He also emphasized its favorable safety and tolerability profile observed during clinical development. In addition, insights from real-world clinical practice were shared, further reinforcing Desidustat's effectiveness in both dialysis-dependent and non-dialysis CKD patients, thereby supporting its applicability across diverse clinical settings

Translating Evidence into Practice

The session also provided practical, implementation-focused guidance, including recommendations on appropriate patient selection, dosing regimens, monitoring parameters, and key considerations for incorporating Desidustat into routine CKD anemia management. Participants engaged in discussions around actionable strategies aimed at optimizing therapy, improving long-term adherence, and enhancing overall patient outcomes.

At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.

Snapshots of Success

Lecture on Novel Therapy to Treat CKD Anemia in India







Developed by:

CME FOUNDATION OF INDIA

Building "A" Sahney Business Centre, 27 Kirol Road, Vidyavihar (W), Mumbai - 400086
Tel: +91 22 61798600 | Website: www.cmefi.co.in